Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Myriad Genetics
(NASDAQ:MYGN)
Intraday
$18.60
0.11
[0.59%]
After-Hours
$18.60
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$18.60
0.11
[0.59%]
At close: Apr 23
$18.60
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Myriad Genetics Stock (NASDAQ:MYGN)
Myriad Genetics Stock (NASDAQ: MYGN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 16, 2024
New Myriad Genetics Published Study Demonstrating PPV For 22122.2 Microdeletion Screening Using Prequel Prenatal Screen
Benzinga Newsdesk
-
Apr 16, 2024, 9:18AM
Tuesday, April 09, 2024
Myriad Genetics Research Shows Reduction In Hospitalizations For Patients With Depression After GeneSight Testing
Benzinga Newsdesk
-
Apr 9, 2024, 8:05AM
Friday, March 22, 2024
Reported Earlier, Myriad Genetics Granted Foundational Patent For Molecular Residual Disease (MRD) With Early Priority Date
Benzinga Newsdesk
-
Mar 22, 2024, 3:14AM
Wednesday, March 20, 2024
Myriad Genetics Says US Patent And Trademark Office Has Granted Patent That Covers Use Of Push-Button Blood Collection Devices For PCR-Based Fetal Sex Determination
Benzinga Newsdesk
-
Mar 20, 2024, 4:08PM
Tuesday, February 27, 2024
Myriad Genetics Sees 2024 Adj. EPS $0.00-$0.05 vs $(0.01) Est., Revenue $820M-$840M vs $819.25M Est.
Benzinga Newsdesk
-
Feb 27, 2024, 5:08PM
Myriad Genetics: Q4 Earnings Insights
Benzinga Insights
-
Feb 27, 2024, 4:50PM
Myriad Genetics Q4 2023 Adj EPS $0.04 Beats $0.01 Estimate, Sales $196.60M Beat $194.78M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 4:47PM
Myriad Genetics And National Cancer Center Hospital East In Japan Collaborate On Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Benzinga Newsdesk
-
Feb 27, 2024, 9:16AM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Myriad Genetics Earnings Preview
Benzinga Insights
-
Feb 26, 2024, 11:01AM
Tuesday, January 30, 2024
Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $31
Benzinga Newsdesk
-
Jan 30, 2024, 8:59AM
Monday, January 29, 2024
Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights
Benzinga Insights
-
Jan 29, 2024, 11:01AM
Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $31
Benzinga Newsdesk
-
Jan 29, 2024, 10:33AM
Friday, January 19, 2024
Myriad Genetics Acquires Precise Tumor, Precise Liquid And Laboratory From Intermountain Precision Genomics; Deal Terms Not Disclosed
Benzinga Newsdesk
-
Jan 19, 2024, 1:28AM
Thursday, December 21, 2023
Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation
Vandana Singh
-
Dec 21, 2023, 1:05PM
Myriad Genetics Appoints Of Scott Leffler As CFO Effective Jan. 29, 2024; Succeeds Bryan Riggsbee; Riggsbee Will Continue As Strategic Advisor Through March 31, 2024, To Ensure A Smooth Transition
Benzinga Newsdesk
-
Dec 21, 2023, 8:33AM
Evaluating Myriad Genetics: Insights From 4 Financial Analysts
Benzinga Insights
-
Dec 21, 2023, 7:00AM
Piper Sandler Initiates Coverage On Myriad Genetics with Neutral Rating, Announces Price Target of $23
Benzinga Newsdesk
-
Dec 21, 2023, 5:36AM
Wednesday, December 20, 2023
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
Benzinga Newsdesk
-
Dec 20, 2023, 8:03AM
Tuesday, December 19, 2023
Wells Fargo Initiates Coverage On Myriad Genetics with Equal-Weight Rating, Announces Price Target of $20
Benzinga Newsdesk
-
Dec 19, 2023, 11:08AM
Thursday, December 14, 2023
Guggenheim Initiates Coverage On Myriad Genetics with Buy Rating, Announces Price Target of $23
Benzinga Newsdesk
-
Dec 14, 2023, 6:36AM
Wednesday, December 13, 2023
Wolfe Research Initiates Coverage On Myriad Genetics with Outperform Rating
Benzinga Newsdesk
-
Dec 13, 2023, 11:59AM
Monday, November 20, 2023
Myriad Genetics Celebrates One Million SneakPeek Results Shared With Expectant Parents
Benzinga Newsdesk
-
Nov 20, 2023, 4:19PM
Friday, November 17, 2023
Myriad Genetics Agrees To Market The Personalis ImmunoID Next Ultra-comprehensive Biomarker Discovery Platform To Its Partners Who Use The MyRisk Hereditary Cancer Test, BRACAnalysis CDx, and/or MyChoice CDx Cancer Tests
Benzinga Newsdesk
-
Nov 17, 2023, 4:05AM
Thursday, November 16, 2023
Myriad Genetics And Personalis Partner To Market Solutions To Pharma Customers
Benzinga Newsdesk
-
Nov 16, 2023, 4:08PM
Thursday, November 09, 2023
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Nov 9, 2023, 1:13PM
AerSale, Topgolf Callaway Brands, Digital Turbine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Lisa Levin
-
Nov 9, 2023, 6:28AM
Wednesday, November 08, 2023
Myriad Genetics Announced $100M Offering Of Common Stock
Benzinga Newsdesk
-
Nov 8, 2023, 5:24PM
Tuesday, November 07, 2023
JP Morgan Maintains Underweight on Myriad Genetics, Lowers Price Target to $14
Benzinga Newsdesk
-
Nov 7, 2023, 3:15PM
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Nov 7, 2023, 1:10PM
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
-
Nov 7, 2023, 10:54AM
Monday, November 06, 2023
Myriad Genetics Q3 Adj EPS $(0.03) Beats $(0.08) Estimate, Sales $191.90M Beat $179.25M Estimate
Benzinga Newsdesk
-
Nov 6, 2023, 4:43PM
Earnings Scheduled For November 6, 2023
Benzinga Insights
-
Nov 6, 2023, 8:24AM
Friday, November 03, 2023
Earnings Outlook For Myriad Genetics
Benzinga Insights
-
Nov 3, 2023, 3:01PM
Wednesday, November 01, 2023
Myriad Genetics Appoints Sam Raha As COO Effective Dec. 11, 2023
Benzinga Newsdesk
-
Nov 1, 2023, 9:11AM
Thursday, October 26, 2023
QIAGEN And Myriad Genetics Partner To Advance Companion Diagnostics Development For Cancer
Benzinga Newsdesk
-
Oct 26, 2023, 8:04AM
Wednesday, October 11, 2023
On Oct 10, 2023, Myriad Genetics Inc Agreed On New Long-Term Agreement With UnitedHealthCare; Contract Amendment Is Effective January 1, 2024 And Runs Through December 31, 2027
Benzinga Newsdesk
-
Oct 11, 2023, 9:04AM
Tuesday, September 19, 2023
Myriad Genetics And Illumina Announced Two Key Milestones In Strategic Partnership To Support Biopharma Clinical Trials
Benzinga Newsdesk
-
Sep 19, 2023, 9:08AM
Monday, September 18, 2023
Myriad Genetics And Leading Cancer Center Collaborate To Study The Use Of Minimal Residual Disease Testing In Breast Cancer
Benzinga Newsdesk
-
Sep 18, 2023, 8:12AM
Monday, August 07, 2023
Myriad Genetics Announces Enhancements To The GeneSight Test To Personalize Mental Health Medication Treatment Decisions Based On Smoking Status
Happy Mohamed
-
Aug 7, 2023, 4:47PM
JP Morgan Maintains Underweight on Myriad Genetics, Lowers Price Target to $17
Benzinga Newsdesk
-
Aug 7, 2023, 11:50AM
Thursday, August 03, 2023
Myriad Genetics Q2 Adj EPS $(0.08), Inline, Sales $183.50M Miss $187.13M Estimate
Benzinga Newsdesk
-
Aug 3, 2023, 5:54PM
Earnings Scheduled For August 3, 2023
Benzinga Insights
-
Aug 3, 2023, 6:59AM
Wednesday, August 02, 2023
Preview: Myriad Genetics's Earnings
Benzinga Insights
-
Aug 2, 2023, 3:01PM
Monday, July 24, 2023
Myriad Genetics Announces Inclusion Of Breast Density To MyRisk With RiskScore Breast Cancer Risk Assessment
Happy Mohamed
-
Jul 24, 2023, 8:23AM
Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $28
Benzinga Newsdesk
-
Jul 24, 2023, 8:21AM
Friday, July 21, 2023
Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $28
Benzinga Newsdesk
-
Jul 21, 2023, 8:16AM
Thursday, June 22, 2023
Cramer Calls Tech Giant A 'Great' Long-Term Play, But In The Short Term It's Just 'Too Hot'
Lisa Levin
-
Jun 22, 2023, 10:49AM
Wednesday, May 24, 2023
Myriad Genetics Adds Folate Receptor Alpha To Precise Oncology Solutions Portfolio To Expand Treatment Options For Women Living With Ovarian Cancer
Happy Mohamed
-
May 24, 2023, 4:13PM
Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $25
Benzinga Newsdesk
-
May 24, 2023, 7:53AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch